The major excitatory neurotransmitter glutamate is involved in the trigeminovascular pain pathway. In the pons, glutamatergic mechanisms are involved in regulating inhibitory descending pain modulation and serotoninergic neurotransmission, as well as modulating the sensory transmission of the trigeminovascular system. Abnormal glutamate levels in the pons may be an important pathophysiological feature of migraine, aiding to attack initiation.
âHow to measure glutamate levels in the pons? This is technically challenging,â Dr Samaira Younis (Danish Headache Centre, Denmark) mentioned. âIn recent years, however, the application of proton magnetic resonance spectroscopy (MRS) has allowed non-invasive measurements of glutamate in various brain structures.â Using this technique to investigate glutamate at different levels of the trigeminovascular system, previous studies have demonstrated alterations during the interictal state of migraine [2,3]. One study recently investigated glutamate levels in the pons during attacks and detected no change [4].
The current study investigated whether glutamate levels in the pontine are altered outside attack cycles [1]. To this end, 34 patients with migraine without aura were scanned when outside an attack cycle using a proton MRS protocol optimised for the pons at 3T (3T 1H-MRS).
Measurements were taken on 2 separate days to increase accuracy and they were compared with similar repeated measurements from 16 healthy controls. Results demonstrated that interictal pontine glutamate levels of migraine patients were not different from those of healthy controls (P=0.098; see Figure). âInterestingly, we found that total creatine levels were markedly increased in patients compared with healthy controls (P=0.009; see Figure).â No correlation was found of glutamate or total creatine levels with migraine attack frequency, days since the last attack, disease duration, or usual pain intensity of attacks.
Figure: Glutamate and total creatine levels in migraine patients and healthy controls [1]

- Younis S, et al. Interictal pontine metabolism in migraine without aura patients: a 3 tesla proton magnetic resonance spectroscopy study. AL066, IHC 2021, 8â12 September.
- Aguila ME, et al. NMR Biomed. 2015;28(7):890â7.
- Arngrim N, et al. Brain. 2016;139(Pt 3):723â37.
- Younis S, et al. J Cereb Blood Flow Metab. 2021;41(3):604â16.
Copyright ©2021 Medicom Medical Publishers
© 2023 The Author(s). Published by Medicom Medical Publishers.
User license: Creative Commons Attribution â NonCommercial (CC BY-NC 4.0)
Posted on
Previous Article
« AI-enabled ECG algorithm predicts atrial fibrillation risk in migraine Next Article
Morphological changes in cluster headache between attacks »
« AI-enabled ECG algorithm predicts atrial fibrillation risk in migraine Next Article
Morphological changes in cluster headache between attacks »
Table of Contents: IHC 2021
Featured articles
Letter from the Editor
COVID-19
Telemedicine beneficial for headache care during the pandemic
Comparison of headaches after SARS-CoV-2 vaccination
Grey matter cortical changes in patients with persistent headache after COVID-19
Increased risk of cerebral venous thrombosis in COVID-19
Patient Perception and Symptoms
Predictors of health-related quality of life in cluster headache
Dry eye disease is more prevalent in migraine
Voice change and throat swelling are cranial autonomic symptoms in primary headache
Association between physical inactivity and headache disorders
Increased suicidal attempts and risks of ideation in medication-overuse headache
Cardioembolic Comorbidities
AI-enabled ECG algorithm predicts atrial fibrillation risk in migraine
Migraine may not be a risk factor for stroke
Imaging
Functional brainstem somatotopy of the trigeminal nerve during nociception
Morphological changes in cluster headache between attacks
Interictal pontine metabolism in migraine patients without aura
Genome-Wide Association Studies
Largest genome-wide association study of migraine to date
Robust evidence that cluster headache has a genetic basis
Pharmacological Treatment
Insights in drug-drug interactions facilitate rational polypharmacy
Rimegepant confers long-term improvements in MMDs
First real-world effectiveness data of erenumab is promising
Galcanezumab effective in patients with episodic or chronic cluster headache
Central effects and affected somatosensory processing with galcanezumab in migraine
Long-term safety and tolerability of atogepant in migraine
Non-Pharmacological Treatment
Occipital nerve stimulation effective and safe in chronic cluster headache
Related Articles
© 2023 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy